EZH2 and cancer: 3-Deazaneplanocin A (DZNEP), the first indirect inhibitor of EZH2, was reported to be a promising cancer-fighting agent for malignant ovarian tumor, with potential to reduce proliferation, induce apoptosis, and inhibit metastasis [209].